TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00978042

Intervention type: DEVICE
Group type: OTHER
Intervention: Juvéderm® VOLUMA XC
Description: Treating Investigator determines the appropriate volume of VOLUMA XC to be injected up to a maximum total of 12 mL for initial and touch-up treatment. One repeat treatment with up to 12 mL may be performed at the Subject's option after study completion.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Juvéderm® VOLUMA XC
Description: Treating Investigator determines the appropriate volume of VOLUMA XC to be injected up to a maximum total of 12 mL for initial and touch-up treatment. One repeat treatment with up to 12 mL may be performed at the Subject's option after study completion.
Study: NCT03110549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMB-607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMB-607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMB-607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMB-607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMB-607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMB-607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMB-607

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT02140619

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: multiple health education interventions

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: multiple health education interventions
Study: NCT00318565

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RF energy delivery for treatment of Typical Atrial flutter
Description: Navistar ThermoCool catheter
Study: NCT02294006

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus plus Octreotide LAR plus Metformin
Description: Everolimus plus Octreotide LAR plus Metformin
Study: NCT04782037

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: L-Methylfolate Calcium
Description: Folic acid is one of the water-soluble B vitamins, which is synthetically-produced and found in fortified foods and supplements. It is essential for the synthesis and repair of DNA and RNA and metabolism of amino acids which are required for cell division. There is damage to the intestinal mucosa in most diarrhea cases; therefore, the role of folic acid has been studied as adjuvant therapy for diarrhea since folic acid plays an important role in the synthesis of DNA especially in rapidly regenerating cells.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: L-Methylfolate Calcium
Description: Folic acid is one of the water-soluble B vitamins, which is synthetically-produced and found in fortified foods and supplements. It is essential for the synthesis and repair of DNA and RNA and metabolism of amino acids which are required for cell division. There is damage to the intestinal mucosa in most diarrhea cases; therefore, the role of folic acid has been studied as adjuvant therapy for diarrhea since folic acid plays an important role in the synthesis of DNA especially in rapidly regenerating cells.
Study: NCT03410927

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAS0728
Description: TAS0728 is an oral HER2 covalent inhibitor investigated in patients with advanced solid tumor harboring HER2 or HER3 abnormalities. It will be administered orally at a starting dose of 50 mg BID each morning and evening and escalated to the DLT. The MTD will be used for the phase 2 arms of the study.
Study: NCT01763463

Intervention type: DRUG
Intervention: New users of ADVAIR DISKUS, ADVAIR HFA (ICS) - containing medications
Description: Patients will be considered a new user of ICS-containing medications if they had not received a prescription for an ICS-containing medication in the year prior to cohort entry. ICS-containing medications could include ICS and ICS/LABA fixed dose combinations combinations. Patients could not use LABD (long-acting beta-agonists and long-acting antimuscarinics) in the year prior or initiate triple therapy (e.g., ICS/LABA/LAMA) as their new user prescription.

Intervention type: DRUG
Intervention: New users of ADVAIR DISKUS, ADVAIR HFA (ICS) - containing medications
Description: Patients will be considered a new user of ICS-containing medications if they had not received a prescription for an ICS-containing medication in the year prior to cohort entry. ICS-containing medications could include ICS and ICS/LABA fixed dose combinations combinations. Patients could not use LABD (long-acting beta-agonists and long-acting antimuscarinics) in the year prior or initiate triple therapy (e.g., ICS/LABA/LAMA) as their new user prescription.

Intervention type: DRUG
Intervention: New users of FLOVENT DISKUS, FLVENT HFA (long-acting bronchodilators (LABD))
Description: Patients will be considered a new user of LABD medications (long-acting beta-agonists or long-acting antimuscarinics but not both) if they had not received a prescription for an LABD medication in the year prior to cohort entry. Patients could not use ICS-containing medications in the year prior to their new use of LABD or initiate triple therapy (e.g., ICS/LABA/LAMA) as their new user prescription.

Intervention type: DRUG
Intervention: New users of FLOVENT DISKUS, FLVENT HFA (long-acting bronchodilators (LABD))
Description: Patients will be considered a new user of LABD medications (long-acting beta-agonists or long-acting antimuscarinics but not both) if they had not received a prescription for an LABD medication in the year prior to cohort entry. Patients could not use ICS-containing medications in the year prior to their new use of LABD or initiate triple therapy (e.g., ICS/LABA/LAMA) as their new user prescription.
Study: NCT03188432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Given IV and IP

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study: NCT03647683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Distraction
Description: Participants are introduced to the concept of distraction. Distracting oneself from the present situation helps with not perceiving pain, painful thoughts or feelings.~Participants are instructed to use this strategy to cope with the following heat stimulus.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat pain
Description: Participants receive heat pain stimuli using the Thermo Sensory Analyser (TSA-II), a commonly used device to study pain sensation and analgesic effects.
Study: NCT03188432

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Cytoreductive Surgery
Description: Undergo CRS
Study: NCT00634114

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 10mg once daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole
Description: 20mg once daily oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: 10mg once daily oral administration
Study: NCT01274455

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Gene Therapy product CYL-02 = plasmid DNA pre-complexed to linear polyethylenimine encoding sst2 + dck::umk genes
Description: Intratumoral injection of the gene therapy product CYL-02 (2,5 ml within the primary tumor under endoscopic ultrasound guidance an under propofol anaesthesia). The intratumor injection of CYL-02 is followed by three IV infusions of Gemcitabine (1000 mg/m2) at 48 hours and then every two weeks. A second Intratumoral injection of the gene therapy product CYL-02 is performed at a same dosage and volume 30 days after the first administration followed by Three infusions of gemcitabine (1000 mg/m2) according the same rhythm (48 hours and every week) and dose.
Study: NCT00960258

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib (BAY73-4506)
Description: The patients will be treated on Day 1 of the first week followed by 6 days off treatment (Cycle 0, single dosing period). After Cycle 0, the patients will be treated with BAY 73-4506 (160 mg once daily orally, 21 days on/ 7 days off schedule). Dose level : 160 mgDose level-1: 120 mgDose level-2: 60 mg
Study: NCT04504435

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3494245
Description: Capsule of 10-250 mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3494245
Description: Capsule of 10-250 mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3494245
Description: Capsule of 10-250 mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK3494245
Description: Capsule of 10-250 mg dose strength will be provided in labelled High Density Polyethylene (HDPE) bottles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules will be provided

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Matching placebo capsules will be provided
Study: NCT02306239

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin
Study: NCT03110549

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT00111813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Vorinostat capsules. Treatment in 21 day cycles (participants receive vorinostat for 14 days followed by a 7 day break).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Vorinostat capsules. Treatment in 21 day cycles (participants receive vorinostat for 14 days followed by a 7 day break).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Vorinostat capsules. Treatment in 21 day cycles (participants receive vorinostat for 14 days followed by a 7 day break).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Vorinostat capsules. Treatment in 21 day cycles (participants receive vorinostat for 14 days followed by a 7 day break).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Vorinostat capsules. Treatment in 21 day cycles (participants receive vorinostat for 14 days followed by a 7 day break).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Vorinostat capsules. Treatment in 21 day cycles (participants receive vorinostat for 14 days followed by a 7 day break).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Bortezomib injection. Given twice weekly for 2 weeks with a 1 week break. Treatment in 21 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Bortezomib injection. Given twice weekly for 2 weeks with a 1 week break. Treatment in 21 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Bortezomib injection. Given twice weekly for 2 weeks with a 1 week break. Treatment in 21 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Bortezomib injection. Given twice weekly for 2 weeks with a 1 week break. Treatment in 21 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Bortezomib injection. Given twice weekly for 2 weeks with a 1 week break. Treatment in 21 day cycles.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Bortezomib injection. Given twice weekly for 2 weeks with a 1 week break. Treatment in 21 day cycles.
Study: NCT00973115

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin CR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simvastatin CR
Study: NCT02320877

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mandibular Advancement Device (Somnomed Flex)
Description: The SomnoDent Flex™ MAS is a custom-made, titratable MAS that is validated in randomized controlled trials described in literature
Study: NCT03554460

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: dual-limb NIV
Description: dual-limb NIV was served with servo i ventilator
Study: NCT01186549

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ephedrine 30microgram/kg
Description: Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine0.5mg/kg -ephedrine30 micrograms/kg
Description: Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ephedrine 70 microgram/kg
Description: Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lidocaine 0.5mg/kg
Description: Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline 2ml
Description: Patients were randomly allocated to one of 5~groups (33 patients per group): lidocaine 0.5 mg/kg(L) ,ephedrine 30micrograms/kg (E30)ephedrine 70micrograms/kg(E70),lidocaine0.5mg/kg -ephedrine30 micrograms/kg(LE) or 2ml saline (S)intravenously.participants in each group receive a single dose of the intervention treatment only.After one minute propofol 2 mg/kg into a dorsal hand vein was injected
Study: NCT02306239

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Norepinephrine
Study: NCT01965912

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kuvan®
Description: Kuvan® oral soluble tablet will be administered once daily along with Phenylalanine-restricted diet for a period of 7 years. Dosage of Kuvan® could range from 5 to 20 milligram per kilogram per day (mg/kg/day), as per Summary of Product Characteristics (SPC).
Study: NCT03647683

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat pain
Description: Participants receive heat pain stimuli using the Thermo Sensory Analyser (TSA-II), a commonly used device to study pain sensation and analgesic effects.
Study: NCT01510717

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AcrySof® IQ ReSTOR® +2.5 D Multifocal IOL Model SN6AD2 [SV25T0]
Description: Multifocal IOL with extended secondary focal point implanted for long-term use over the lifetime of the cataract patient

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: AcrySof® IQ Monofocal IOL Model SN60WF
Description: Monofocal IOL implanted for long-term use over the lifetime of the cataract patient
Study: NCT01845844

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ranibizumab 0.3mg/0.05cc
Description: Group A (Arm A) will receive monthly 0.3mg/0.05cc intravitreal injections for 12 consecutive months.~Group B (Arm B) will receive monthly 0.3mg/0.05cc intravitreal injections for the first six months and then PRN for the remaining 6 months per protocol specified criteria.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranibizumab 0.3mg/0.05cc
Description: Group A (Arm A) will receive monthly 0.3mg/0.05cc intravitreal injections for 12 consecutive months.~Group B (Arm B) will receive monthly 0.3mg/0.05cc intravitreal injections for the first six months and then PRN for the remaining 6 months per protocol specified criteria.
Study: NCT03754959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1358894
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Film-coated tablet
Study: NCT02274844

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Living Well with Diabetes Program
Description: The intervention participants will receive the Living Well with Diabetes Program. The program will consist of educational DVDs with integrated storytelling about how community members accepted their disease and overcame barriers to medication adherence, plus one-on-one telephonic peer coaching
Study: NCT02453906

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: XNKQ
Description: stimulation at 5 acupuncture points according to XNKQ acupuncture

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control 1
Description: no stimulation at 5 acupuncture points according to XNKQ acupuncture

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control 2
Description: stimulation at 5 control points

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control 3
Description: no stimulation at 5 control points
Study: NCT01030341

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CGMS and insulin pump
Description: Use of continuous glucose monitoring system and insulin pump
Study: NCT00845806

Intervention type: OTHER
Intervention: MRI
Description: All subjects will be asked to lay in an MRI for about an hour while reading Arabic diacritic characters
Study: NCT03951896

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: A venous blood sample of 8.5 ml were obtained from all patients. For the treatment group, the blood samples were treated with 1.5 ml ACD-A or sodium citrate to achieve anticoagulation. The blood was then centrifugated for 5 minutes with RCF 1200 G velocity to clump red blood cells, and then centrifugated for 10 minutes in same velocity to obtain platelet concentrate. 2 ml's of the resulting platelet rich plasma was injected to the shoulder of the subjects.All of the injections were done every two weeks, for a total of 3 times using 21 G injection needles with injection technique of posterior approach.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Saline injection
Description: 2 ml's of NaCl solution with 0,9% concentration was applied to the shoulders of the participants.
Study: NCT02528123

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Small incision lenticule extraction
Description: The VisuMax femtosecond laser is used to create two interfaces that define a refractive lenticule of stromal tissue and a 2mm wide tunnel to connect the upper layer to the corneal surface. The lenticule is manually dissected and removed through the small 2mm incision without the need to create a flap as in LASIK.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin and dexamethasone
Description: Tobramycin and dexamethasone (Tobradex) eye drops will be used four times a day for 1 week after the procedure

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Description: Ofloxacin (Exocin) eye drops will be used four times a day for 1 week after the procedure
Study: NCT03754959

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Film-coated tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Solution for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Solution for injection
Study: NCT03792620

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Cyclo Thal Dex Daratumumab
Description: Cyclo Thal Dex Daratumumab
Study: NCT02405299

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: experimental groupe
Description: exercices of cognitive and neuropsychological stimulation of inhibition (paper and pencil exercises and computerized exercises) created for the experience: cognitive stimulation exercises for children in the form of cognitive and metacognitive games with rehabilitation objective disorder of inhibition
Study: NCT02904642

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS reminder
Description: Caregivers will receive two text message reminders for their child's measles immunization scheduled for 9 months of age

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMS reminder
Description: Caregivers will receive two text message reminders for their child's measles immunization scheduled for 9 months of age

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Unconditional Incentive
Description: A mobile-money incentive in the amount of 150 Kenyan Shillings will be transferred to the enrolled caregiver's mobile phone when the child reaches nine months of age
Study: NCT02405299

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: experimental groupe
Description: exercices of cognitive and neuropsychological stimulation of inhibition (paper and pencil exercises and computerized exercises) created for the experience: cognitive stimulation exercises for children in the form of cognitive and metacognitive games with rehabilitation objective disorder of inhibition